TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9864075

Group type: COMPARATOR
Intervention: Fluvoxamine 300 mg/day + Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 300 mg/day + Pindolol 7.5 mg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluvoxamine + Pindolol
Number of subjects: 72
Study: 7838642

Group type: EXPERIMENTAL
Intervention: Rapid injection of indomethacin (3 doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of indomethacin (over 36 hours)
Number of subjects: 18
Study: 2146697

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 687017

Group type: EXPERIMENTAL
Intervention: Long-term extracorporeal membrane oxygenation (ECMO)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional therapy without ECMO
Number of subjects: 90
Study: 31418062

Group type: EXPERIMENTAL
Intervention: Early initiation of dialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late initiation of dialysis
Number of subjects: 0
Study: 31159495

Group type: EXPERIMENTAL
Intervention: Nordic diet group (NG)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional diet group (CG)
Number of subjects: 250
Study: 27669162

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavior therapy (CBT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive therapy (CT)
Number of subjects: 33
Study: 25467199

Group type: EXPERIMENTAL
Intervention: Run/walk strategy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Running only
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (Run/walk and Running only)
Number of subjects: 42
Study: 25257273

Group type: EXPERIMENTAL
Intervention: Drug therapy (oral antibiotics, mometasone furoate nasal spray, leukotriene receptor antagonist, mucoactive medications) for 3 months
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Conservative treatment (drug therapy plus negative pressure of sputum aspiration) for 3 months
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Coblation adenotonsillectomy after 3 days conservative treatment and postoperative drug therapy for 2 weeks (B2 subgroup)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Coblation adenotonsillectomy after 2 weeks conservative treatment and postoperative drug therapy for 3 months (B3 subgroup)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Drug therapy for 3 months (A1 subgroup)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Conservative treatment for 3 months (B1 subgroup)
Number of subjects: 386
Study: 22889492

Group type: EXPERIMENTAL
Intervention: Pentraxin-3 levels in women with primary unexplained recurrent pregnancy loss
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pentraxin-3 levels in apparently healthy pregnant women
Number of subjects: 90
Study: 19666456

Group type: EXPERIMENTAL
Intervention: Active-online (tailored intervention)
Number of subjects: 1531

Group type: EXPERIMENTAL
Intervention: Active-online (tailored intervention) and spontaneous users
Number of subjects: 1531

Group type: COMPARATOR
Intervention: Nontailored website (control group)
Number of subjects: 1531
Study: 17766475

Group type: EXPERIMENTAL
Intervention: Treadmill exercise in a lower body negative pressure chamber and resistance exercise (EX group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No exercise (No-EX group)
Number of subjects: 16
Study: 15703143

Group type: EXPERIMENTAL
Intervention: Pure tone audiometry (PTA)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Otoacoustic emission (OAE) testing
Number of subjects: 2

Group type: COMPARATOR
Intervention: Both groups (PTA and OAE)
Number of subjects: 2
Study: 12135536

Group type: EXPERIMENTAL
Intervention: Adderall
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9516206

Group type: EXPERIMENTAL
Intervention: Bed-sharing
Number of subjects: 35

Group type: COMPARATOR
Intervention: Solitary sleeping
Number of subjects: 35
Study: 7641173

Group type: EXPERIMENTAL
Intervention: 50 ml of ioversol 320 mg I/ml
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 75 ml of ioversol 320 mg I/ml
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 ml of ioversol 320 mg I/ml
Number of subjects: 100

Group type: COMPARATOR
Intervention: 120 ml of ioversol 320 mg I/ml
Number of subjects: 100
Study: 29377181

Group type: EXPERIMENTAL
Intervention: Amino Acid-based commercial ORT beverage
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sports drink (SP)
Number of subjects: 26
Study: 27350420

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24031044

Group type: EXPERIMENTAL
Intervention: LigaSure® (LS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 100
Study: 22728911

Group type: EXPERIMENTAL
Intervention: SMS reminder at 10-12 weeks post-treatment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: SMS reminder with incentive payment on clinic attendance
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard advice from clinician (control group)
Number of subjects: 62
Study: 20233429

Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 4
Study: 18755220

Group type: EXPERIMENTAL
Intervention: Boceprevir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment of PEG-IFN alpha-2b and boceprevir
Number of subjects: 0
Study: 17145598

Group type: EXPERIMENTAL
Intervention: Paracetamol 1g four times daily for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15095779

Group type: EXPERIMENTAL
Intervention: Annual FOB screening
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Biennial FOB screening
Number of subjects: 2000
Study: 10909264

Group type: EXPERIMENTAL
Intervention: Honey-treated Pericarpium Citri Grandis decoction
Number of subjects: 6

Group type: COMPARATOR
Intervention: Untreated Pericarpium Citri Grandis decoction
Number of subjects: 6
Study: 8719187

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg bolus followed by 0.20 mg/kg‐1/min‐1 infusion)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Midazolam (90 micrograms/kg 2 min before induction) followed by half-strength propofol (1 mg/kg bolus with 0.10 mg/kg‐1/min‐1 infusion)
Number of subjects: 16
Study: 1574844

Group type: EXPERIMENTAL
Intervention: Gaussian‐truncated sinewave gratings with varying stimulus contrast and bandwidth
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Gaussian‐truncated sinewave gratings with constant spatial frequency bandwidth (0.5 octave) and suprathreshold contrast value (5 x detection threshold)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Reference spatial frequency gratings varying from 1 to 8 c/deg
Number of subjects: 2
Study: 4065186

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbachol
Number of subjects: 8
Study: 30498037

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 70
Study: 27797931

Group type: EXPERIMENTAL
Intervention: HypoAware intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control (care as usual)
Number of subjects: 137
Study: 25740578

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 60
Study: 22728633

Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius (4x10^9 colony forming units/g daily for 12 weeks)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo (daily for 12 weeks)
Number of subjects: 199
Study: 19951274

Group type: EXPERIMENTAL
Intervention: Rivastigmine (up to 9 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19036143

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy with Paclitaxel (50 mg/m2) and Carboplatin (AUC = 2) followed by surgery
Number of subjects: 350

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 350
Study: 16174497

Group type: EXPERIMENTAL
Intervention: MTPJ arthrodesis
Number of subjects: 63

Group type: COMPARATOR
Intervention: MTPJ arthroplasty
Number of subjects: 63
Study: 12970783

Group type: EXPERIMENTAL
Intervention: Standard induction chemotherapy regimen (TAD 2+7) with GM-CSF
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard induction chemotherapy regimen (TAD 2+7) without GM-CSF
Number of subjects: 93
Study: 11605609

Group type: EXPERIMENTAL
Intervention: Early intervention program including motor, cognitive, speech development and social behavior.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional care group (control).
Number of subjects: 156
Study: 8681919

Group type: EXPERIMENTAL
Intervention: IMB model‐based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No‐treatment control condition
Number of subjects: 0
Study: 2052056

Group type: EXPERIMENTAL
Intervention: Acetaminophen (4000 mg per day)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Ibuprofen (low dose, 1200 mg per day)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Ibuprofen (high dose, 2400 mg per day)
Number of subjects: 184
Study: 6361788

Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suprofen 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28556500

Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha therapy in Group I (n = 15)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (Group II, n = 19)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline evaluation for all patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline PSG results for all patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline PSQI and snoring score in Group I
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PSG parameters at third month of anti-TNF-alpha therapy in Group I
Number of subjects: 34
Study: 27451927

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet-B
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Psoralen plus ultraviolet-A
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Broadband ultraviolet-A
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (sun-protected skin from 21 subjects with no dermatological disease)
Number of subjects: 63
Study: 24757146

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NEXA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quadriceps strengthening (QS)
Number of subjects: 100
Study: 23571259

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with Ologen implant
Number of subjects: 33

Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin C (MMC)
Number of subjects: 33
Study: 20100913

Group type: EXPERIMENTAL
Intervention: Pamapimod (300 mg once daily for 10 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 22
Study: 17445309

Group type: EXPERIMENTAL
Intervention: One-day prophylactic antibiotic
Number of subjects: 53

Group type: COMPARATOR
Intervention: Three-day prophylactic antibiotic
Number of subjects: 53
Study: 16627043

Group type: EXPERIMENTAL
Intervention: ACIDFORM 0-30 min before intercourse
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ACIDFORM 8-10 h before intercourse
Number of subjects: 20

Group type: COMPARATOR
Intervention: N-9 0-30 min after a control cycle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ACIDFORM (general use)
Number of subjects: 20
Study: 15378774

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b 3 MU/TIW for 6 months in group Ia (N=15)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b 3 MU/TIW for 6 months in group Ib (N=17)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Interferon-alpha 2b 3 MU/TIW for 6 months in group II (N=62)
Number of subjects: 138
Study: 11048993

Group type: EXPERIMENTAL
Intervention: Basiliximab plus dual immunosuppressive therapy (cyclosporine modified [Neoral] and corticosteroids)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo with dual immunosuppressive therapy (cyclosporine modified [Neoral] and corticosteroids)
Number of subjects: 346
Study: 9066996

Group type: EXPERIMENTAL
Intervention: Daily cigarette consumption (20 or more cigarettes per day)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Exposure to neuroleptics
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Dyskinetic group (mean Abnormal Involuntary Movements Scale score)
Number of subjects: 559
Study: 8389026

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 4 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 3303885

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30354996

Group type: EXPERIMENTAL
Intervention: Serum TMAO levels (measured in μmol/L)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Serum TMAO levels (≥1.79 μmol/L)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Serum TMAO levels (≥3.19 μmol/L)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Interaction between TMAO and folate levels (≥7.7 ng/mL versus <7.7 ng/mL)
Number of subjects: 1244
Study: 27769274

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 20
Study: 25031198

Group type: EXPERIMENTAL
Intervention: liraglutide + metformin
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo + metformin
Number of subjects: 40
Study: 22499010

Group type: EXPERIMENTAL
Intervention: Drug conservation arm (440 subjects)
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Viral suppression arm (436 subjects)
Number of subjects: 876
Study: 20139214

Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Midstream urine
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Dipstick
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Symptom score
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Delayed antibiotics
Number of subjects: 309
Study: 18843900

Group type: COMPARATOR
Intervention: Oral metronidazole 500 mg twice a day for seven days
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: One vaginal tablet containing freeze-dried Lactobacillus rhamnosus once a week at bedtime for two months starting one week after the last antibiotic administration
Number of subjects: 84
Study: 15838410

Group type: EXPERIMENTAL
Intervention: Computer-generated care suggestions for CHF
Number of subjects: 774
Study: 12218528

Group type: EXPERIMENTAL
Intervention: Mivacurium (0.1 mg/kg) immediately after loss of consciousness (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mivacurium after 15 min of anesthesia with propofol alone (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mivacurium after 15 min of anesthesia with propofol and N O (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 30
Study: 10487666

Group type: EXPERIMENTAL
Intervention: GH treatment at 6 IU/m2 body surface-day
Number of subjects: 79

Group type: COMPARATOR
Intervention: GH treatment at 3 IU/m2 body surface-day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: GH treatment (both doses)
Number of subjects: 79
Study: 8598656

Group type: EXPERIMENTAL
Intervention: Sequential pneumatic compression devices during surgery and 2 days postoperatively (Group 1, n = 25)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (5000 U q 12 hr) starting 1 hr before surgery and for 7 days postop (Group 2, n = 38)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No prophylaxis (Control Group 3, n = 45)
Number of subjects: 108
Study: 2063698

Group type: EXPERIMENTAL
Intervention: Nicotine fading with enriched cohesion
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Nicotine fading with standard cohesion
Number of subjects: 353

Group type: COMPARATOR
Intervention: Satiation technique
Number of subjects: 353
Study: 6276949

Group type: EXPERIMENTAL
Intervention: Peripheral intravenous nutrition (PIVN) with chemotherapy (adriamycin, vincristine, VP-16-213, and cyclophosphamide)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Chemotherapy control group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Peripheral intravenous nutrition (PIVN) with chemotherapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (PIVN and control)
Number of subjects: 39
Study: 30232094

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) with a paper guideline to target glucose control (2.6-10 mmol/L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard neonatal care (masked CGM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 20
Study: 27705875

Group type: EXPERIMENTAL
Intervention: Sampling-based learning control (SLC) approach with a gradient flow algorithm
Number of subjects: 0
Study: 25664818

Group type: EXPERIMENTAL
Intervention: Portion-controlled meals (PCMs) with fruits and vegetables and increased physical activity during weight loss (0-6 months)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Portion-controlled meals (PCMs) during weight maintenance (6-18 months)
Number of subjects: 197
Study: 24336477

Group type: EXPERIMENTAL
Intervention: Mulligan SNAGs
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Maitland mobilizations
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mulligan SNAGs and Maitland mobilizations
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All groups (Mulligan SNAGs, Maitland mobilizations, and placebo)
Number of subjects: 86
Study: 22492681

Group type: EXPERIMENTAL
Intervention: PALS (Physical Activity Leaders) intervention, n=50
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group, n=50
Number of subjects: 100
Study: 20123776

Group type: EXPERIMENTAL
Intervention: Intervention group (in-hospital counseling session)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 101
Study: 17636113

Group type: EXPERIMENTAL
Intervention: Acetaminophen (15 mg/kg 4 times a day)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Naproxen (5 mg/kg 4 times a day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 77

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 77

Group type: COMPARATOR
Intervention: Acetaminophen and Naproxen
Number of subjects: 77
Study: 16082623

Group type: EXPERIMENTAL
Intervention: MMP-3 genotypes (5A5A, 5A6A, 6A6A)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: PAI-1 genotypes (4G4G, 4G5G, 5G5G)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: MMP-2, MMP-9, MMP-12 genotypes
Number of subjects: 455
Study: 12237200

Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo blockade (saline)
Number of subjects: 88
Study: 10409478

Group type: EXPERIMENTAL
Intervention: 1 mg of sublingual 17beta-oestradiol (E(2))
Number of subjects: 30
Study: 8536451

Group type: EXPERIMENTAL
Intervention: FlexiGard IUD
Number of subjects: 4286

Group type: COMPARATOR
Intervention: TCu 380A IUD
Number of subjects: 4286
Study: 2209513

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 201

Group type: COMPARATOR
Intervention: Whey-hydrolysate formula
Number of subjects: 201

Group type: COMPARATOR
Intervention: Acidified formula
Number of subjects: 201

Group type: COMPARATOR
Intervention: Whey-predominant formula
Number of subjects: 201

Group type: COMPARATOR
Intervention: Casein-predominant formulae
Number of subjects: 201

Group type: COMPARATOR
Intervention: Follow-up formulae
Number of subjects: 201

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: GOR
Number of subjects: 201
Study: 6835896

Group type: EXPERIMENTAL
Intervention: Intravenous meptazinol 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31035395

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence score increase
Number of subjects: 1936

Group type: EXPERIMENTAL
Intervention: High adherence to the Mediterranean diet
Number of subjects: 1936

Group type: COMPARATOR
Intervention: Obese participants
Number of subjects: 1936
Study: 29980607

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 52
Study: 26218077

Group type: EXPERIMENTAL
Intervention: 5-Azacytidine (5-AZA) at a dose of 75 mg/m2 s.c. administered on a schedule of 5 days on/weekend off/2 days on (5/2/2)
Number of subjects: 56
Study: 24342746

Group type: EXPERIMENTAL
Intervention: Hépar 1 group (1 L Hépar and 0.5 L natural low‐mineral water daily)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Hépar 0.5 group (0.5 L Hépar and 1 L natural low‐mineral water daily)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (1.5 L natural low‐mineral water daily)
Number of subjects: 244
Study: 22369335

Group type: EXPERIMENTAL
Intervention: Goal-directed interventions observed by children
Number of subjects: 24

Group type: COMPARATOR
Intervention: Temporal reversal of cause and effect
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Human interventions leading to covariations
Number of subjects: 24
Study: 19013613

Group type: EXPERIMENTAL
Intervention: Macroplastique injection
Number of subjects: 247

Group type: COMPARATOR
Intervention: Contigen injection
Number of subjects: 247
Study: 20439193

Group type: EXPERIMENTAL
Intervention: WBRT + temozolomide (75 mg/m2/day for 21 or 28 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: WBRT alone (30 Gy in 10 fractions)
Number of subjects: 95
Study: 15607839

Group type: EXPERIMENTAL
Intervention: Tincture of opium (TO)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Morphine (MO)
Number of subjects: 33
Study: 12654206

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 378

Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 378